MYD88 mutation status does not impact overall survival in Waldenstr öm macroglobulinemia

In conclusion, MYD88L265P mutation does not appear to be a determinant of outcome, and its presence may not be a disease‐defining feature in WM. Our findings warrant external validation, preferably through prospective studies.

Source: American Journal of Hematology - November 17, 2017 Category: Hematology Authors: Jithma P. Abeykoon, Jonas Paludo, Rebecca L. King, Stephen M. Ansell, Morie A. Gertz, Betsy R. LaPlant, Alese E. Halvorson, Wilson I. Gonsalves, David Dingli, Hong Fang, S. Vincent Rajkumar, Martha Q. Lacy, Rong He, Taxiarchis Kourelis, Craig B. Reeder, A Tags: RESEARCH ARTICLE Source Type: research